ASCO

Basilea Pharmaceutica updates on clinical phase 1/2a program with its anticancer drug candidate BAL101553 at American Society of Clinical Oncology (ASCO)

BASEL, 09-Jun-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase…

7 years ago

Roche to present 19 approved and investigational medicines at American Society of Clinical Oncology (ASCO) Annual Meeting, 3rd – 7th June in Chicago

19 Roche medicines are included in more than 200 abstracts during ASCO 2016 New results for cancer immunotherapy atezolizumab in…

8 years ago